SEED Technology

SEED Therapeutics is a clinical-stage biotechnology company pioneering the discovery and development of targeted protein degradation (TPD) therapeutics, specifically molecular glues. A subsidiary of BeyondSpring, the company utilizes its proprietary RITE3™ platform to design small molecules that reprogram E3 ubiquitin ligases to eliminate disease-causing proteins that were previously considered "undruggable." SEED has established significant strategic partnerships with Eli Lilly and Eisai to advance its pipeline in oncology and neurodegeneration. Its lead candidate, ST-01156, is a brain-penetrant RBM39 degrader currently in Phase 1 clinical trials for the treatment of Ewing sarcoma and other RBM39-dependent cancers.